Compare SOWG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOWG | XLO |
|---|---|---|
| Founded | 2010 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.9M | 56.9M |
| IPO Year | 2011 | 2021 |
| Metric | SOWG | XLO |
|---|---|---|
| Price | $3.23 | $9.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 14.9K | 9.5K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.10 | $0.46 |
| 52 Week High | $4.45 | $9.90 |
| Indicator | SOWG | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 48.51 |
| Support Level | $2.45 | $8.52 |
| Resistance Level | $3.65 | $9.15 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 5.28 | 57.33 |
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.